Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28624097 | 0.90 | HRH3 (0.71) | HRH3MAPK14KDM4EALDH1A1NPC1 | |
| SCHEMBL4815426 | 0.82 | HRH3 (0.79) | HRH3MAPK14KDM4EALDH1A1NPC1 | |
| SCHEMBL3504559 | 0.81 | USP2 (0.58) | HRH3KDM4EALDH1A1NPC1MAOA | |
| SCHEMBL14287616 | 0.80 | HRH3 (0.87) | HRH3MAOAMAOBKMT2A | |
| SCHEMBL8571844 | 0.79 | KDM4E (0.62) | HRH3MAPK14KDM4EALDH1A1NPC1 | |
| SCHEMBL5604414 | 0.79 | KDM4E (0.62) | MAPK14KDM4EALDH1A1NPC1MEN1 | |
| Hydrochloric Acid SCHEMBL11606453 | 0.78 | KDM4E (0.60) | MAPK14KDM4EALDH1A1NPC1MEN1 | |
| Hydrochloric Acid SCHEMBL11602807 | 0.78 | KDM4E (0.60) | MAPK14KDM4EALDH1A1NPC1MEN1 | |
| SCHEMBL13027989 | 0.78 | AURKA (0.59) | KDM4EALDH1A1 | |
| SCHEMBL13062565 | 0.78 | KDM4E (0.54) | HRH3KDM4EALDH1A1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158024-A1 | TRICYCLIC NECROSTATIN COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-06-20 | — | — | US | disclosed |
| US-20130158024-A1 | TRICYCLIC NECROSTATIN COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-06-20 | — | — | US | disclosed |
| US-8324262-B2 | Tricyclic necrostatin compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324262-B2 | Tricyclic necrostatin compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100190836-A1 | Compounds, Screens, and Methods of Treatment | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-07-29 | — | — | US | disclosed |
| US-20100190836-A1 | Compounds, Screens, and Methods of Treatment | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190836-A1 | Compounds, Screens, and Methods of Treatment | NLN, HTRA2, CLN6 | HRH3 2983/4885MAPK14 2848/4885KDM4E 4533/4885 |
| US-20130158024-A1 | TRICYCLIC NECROSTATIN COMPOUNDS | HTRA2, AIFM1, BAD | HRH3 4386/4885MAPK14 1840/4885KDM4E 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.